Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study

被引：0
|
作者：
Fassnacht, M. [1 ]
Kappeler, C. [2 ]
Healy, D. P. [3 ]
Baumer, C. [4 ]
Meinhardt, G. [3 ]
Elisei, R. [5 ]
Schlumberger, M. [6 ,7 ]
Brose, M. S. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Wurzburg, Germany
[2] Bayer Pharma AG, Berlin, Germany
[3] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[4] BIOP AG, Basel, Switzerland
[5] Univ Pisa, Pisa, Italy
[6] Gustave Roussy, Villejuif, France
[7] Univ Paris 11, Villejuif, France
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0277
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [1] Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study.
    Kappeler, Christian
    Healy, Dennis P.
    Baumer, Christoph
    Meinhardt, Gerold
    Elisei, Rossella
    Schlumberger, Martin
    Brose, Marcia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Prognostic and predictive factors correlated with treatment outcomes for radioactive Iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or placebo on the phase III DECISION trial
    Paschke, R.
    Schlumberger, M.
    Elisei, R.
    Pacini, F.
    Jarzab, B.
    Giannetta, L.
    Bastholt, L.
    de la Fouchardiere, C.
    Worden, F. P.
    Shong, Y. K.
    Smit, J. W.
    Kappeler, C.
    Molnar, I
    Brose, M. S.
    Oncology Research and Treatment, 2015, 38 : 26 - 26
  • [3] Management of thyroid stimulating hormone (TSH) and possible impact on outcomes for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving sorafenib or placebo on the phase III DECISION trial
    Fassnacht, M.
    Smit, J. W.
    Schiumberger, M.
    Kappeler, C.
    Meinhardt, G.
    Brose, M. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 8 - 9
  • [4] Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer
    Leboulleux, S.
    Lee, E. K.
    Bastholt, L.
    Tahara, M.
    Wirth, L. J.
    Sherman, S. I.
    Robinson, B. G.
    Teng, A.
    Joshi, P.
    Misir, S.
    Dutcus, C. E.
    Tuttle, R. M.
    Schlumberger, M. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial
    Brose, M. S.
    Nutting, C.
    Shong, Y. K.
    Sherman, S. I.
    Smit, J. W. A.
    Chung, J.
    Molnar, I.
    Jeffers, M.
    Pena, C.
    Schlumberger, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S745 - S745
  • [6] Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
    Wilson, Leslie
    Huang, Wei
    Chen, Linda
    Ting, Jie
    Cao, Vicky
    THYROID, 2017, 27 (08) : 1043 - 1052
  • [7] COST EFFECTIVENESS OF LENVATINIB, SORAFENIB, AND PLACEBO IN TREATMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Huang, W.
    Chen, L.
    Cao, V
    Sung, H.
    Yokokura, M.
    Ting, J.
    Wilson, L.
    VALUE IN HEALTH, 2016, 19 (03) : A204 - A204
  • [8] Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
    Huillard, Olivier
    Jouinot, Anne
    Tlemsani, Camille
    Brose, Marcia S.
    Arrondeau, Jennifer
    Meinhardt, Gerold
    Fellous, Marc
    De Sanctis, Yoriko
    Schlumberger, Martin
    Goldwasser, Francois
    THYROID, 2019, 29 (12) : 1820 - 1827
  • [9] A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
    Zheng, Xiangqian
    Xu, Zhengang
    Ji, Qinghai
    Ge, Minghua
    Shi, Feng
    Qin, Jianwu
    Wang, Feng
    Chen, Guang
    Zhang, Yuan
    Huang, Rui
    Tan, Jian
    Huang, Tao
    Li, Sijin
    Lv, Zhongwei
    Lin, Yansong
    Guo, Zhuming
    Kubota, Tomoki
    Suzuki, Takuya
    Ikezawa, Hiroki
    Gao, Ming
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5502 - 5509
  • [10] Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the phase 3 DECISION trial
    Kappeler, C.
    Meinhardt, G.
    Elisei, R.
    Brose, M.
    Schlumberger, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345